RXST

RxSight, Inc.

Fundamental data last updated:August 25, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

 


Analyze RXST on TradingView

VALUATION

P/E

-4.93

Market Cap ($M USD)

$230.41M

Forward P/E

-4.67

PEG

0.84

PRICE TO SALES

1.81

PRICE TO BOOK

0.86

EV / EBITDA

-4.47

5-Year Average P/E

Free Cash Flow Yield

-9.37%

DCF Value

$-243.33

Graham Number

N/A

Price to FCF

-10.68

EV to FCF

-10.36

Earnings Yield

-20.29%

FCF Yield

-9.37%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.13

Next Year EPS Growth Estimate

-$1.19

Next Year Revenue Growth Estimate

$154.98M

Return on Equity (ROE)

-17.01%

FREE CASH FLOW

Operating Margin

-43.42%

Debt-to-Equity

0.04

Piotroski F-Score

2

Altman Z-Score

1.60

Return on Invested Capital (ROIC)

-20.01%

Current Ratio

10.20

Quick Ratio

8.93

Net Debt to EBITDA

0.13

Interest Coverage

-5534.60

Gross Profit margin

77.02%

FCF PER SHARE

$-0.52

REVENUE PER SHARE

$3.09

Analyze RXST on TradingView

Gainseekers Quantitative Analysis

Summary

RXST’s valuation is a paradox of extremes. Despite a snapshot price trading dramatically below its DCF value, the negative earnings yield and a Forward P/E ratio in the red signal a company hemorrhaging profitability. The Altman Z-score of 1.73 suggests financial distress, while the PEG ratio under 1.0 hints at potential undervaluation if growth materializes. However, the market’s consensus rating of “Hold” reflects skepticism about its turnaround prospects. This is a stock priced for a gamble, not a guarantee.

AI Exposure / Tech Reliance

Operating in the Medical Devices industry, RXST is positioned at the intersection of healthcare and technology. The sector's inherent demand for innovation means the company must continuously adapt to AI advancements to maintain relevance. Its ability to integrate cutting-edge tech into its products will be crucial for long-term resilience.

The Bull Case

For the bold investor, RXST offers a tantalizing prospect. The low Debt/Equity ratio of 0.04 and a robust Current Ratio of over 10 highlight a fortress-like balance sheet. Despite a dismal Piotroski F-Score of 2, the company's gross profit margin of 77% indicates strong pricing power. If management can harness this capital efficiency, there's potential for significant upside.

The Bear Case

Yet, the bear case is formidable. With an operating margin of -43.42% and a ROIC of -20.01%, RXST is bleeding cash. Its Price/Book ratio below 1.0 might seem attractive, but the negative FCF Yield and Price to FCF ratio of -11.22 reveal a company struggling to generate cash. The technical overextension near its 52-week high further underscores the risk of a pullback.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$10.25

Institutional Ownership %

1-Year Beta

1.24

Insider Buying % (6 Mo)

Distance to 52-Week High

193.93%

Distance to 52-Week Low

4.78%

EARNINGS SURPRISE %

-27.14%

50-DAY SMA

$6.60

200-DAY SMA

$8.64

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.